Skip to main content

Table 2 Absorbed organs dose per administered activity (± SD) for 64CuCl2

From: Biokinetic and dosimetric aspects of 64CuCl2 in human prostate cancer: possible theranostic implications

Organ Absorbed organ dose per administered activity (mGy/MBq)
Adrenals 2.54E-2 (± 6.60E-3)
Brain 1.04E-2 (± 3.95E-3)
Breasts 1.22E-2 (± 4.07E-3)
Gallbladder wall 7.82E-2 (± 2.99E-2)
Lower larger intestine wall 1.25E-2 (± 4.76E-3)
Upper large intestine wall 1.78E-2 (± 5.31E-3)
Small intestine 1.62E-2 (± 5.42E-3)
Stomach wall 1.70E-2 (± 5.48E-3)
Heart wall 1.80E-2 (± 5.30E-3)
Kidneys 1.39E-1 (± 3.72E-2)
Liver 2.71E-1 (± 3.37E-2)
Lungs 1.64E-2 (± 4.88E-3)
Muscle 1.34E-2 (± 4.51E-3)
Pancreas 8.39E-2 (± 4.03E-2)
Red marrow 2.26E-2 (± 9.04E-3)
Osteogenic cells 3.00E-2 (± 1.16E-2)
Skin 1.09E-2 (± 3.84E-3)
Spleen 3.63E-2 (± 1.37E-2)
Testes 1.10E-2 (± 4.14E-3)
Thymus 1.31E-2 (± 4.53E-3)
Thyroid 1.16E-2 (± 4.31E-3)
Urinary bladder wall 1.27E-2 (± 4.69E-3)
Salivary glands 3.70E-2 (± 3.70E-2)
Total body 2.09E-2 (± 5.61E-3)
Effective dose ICRP 60 (mSv/MBq) 3.10E-2 (± 8.07E-3)
Effective dose ICRP 103 (mSv/MBq) 2.91E-2 (± 7.83E-3)